Sort:
Clinical Research Issue
Application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer
Chinese Journal of Multiple Organ Diseases in the Elderly 2026, 25(2): 97-101
Published: 28 February 2026
Abstract PDF (475.9 KB) Collect
Downloads:0
Objective

To analyze the application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC).

Methods

A total of 206 elderly patients with advanced NSCLC admitted to the First People′s Hospital of Liangshan Yi Autonomous Prefecture from January 2018 to August 2023 were selected as the study subjects. According to the treatment regimens, the patients were divided into an immunotherapy group (n = 101) treated with programmed cell death receptor 1 (PD-1) immune checkpoint inhibitors and a combination therapy group (n = 105) treated with PD-1 inhibitors combined with volume rotation intensity modulated radiation therapy (VMAT). The two groups were compare in the clinical efficacy, T-cell subsets (CD4+, CD8+, CD4+/CD8+), pulmonary function [forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC] before and after treatment, and adverse reactions. SPSS 25.0 was used for data processing. Kaplan-Meier survival curves were used to analyze the difference in progression-free survival (PFS) at 15 months after the beginning of treatment in the two groups.

Results

The objective response rate (50.48% vs 35.64%) and disease control rate (81.90% vs 69.31%) in the combination therapy group were higher than those in the immunotherapy group (P<0.05). After the treatment, CD4+, CD4+/CD8+, FEV1, FVC and FEV1/FVC in both groups increased as compared with before treatment (P<0.05), and the above indicators in the combination therapy group after treatment were higher than those in the immunotherapy group (P<0.05). With 15 months of treatment as the end point, the disease progression rate was 30.48% (32/105) in the combination therapy group and 48.51% (49/101) in the immunotherapy group. Kaplan-Meier curve analysis showed that the median PFS of the combination therapy group [12.41 months (95%CI 11.564-13.255)] was significantly longer than that of the immunotherapy group [10.56 months (95%CI 9.576-11.553)], and the difference was statistically significant (Log-rank χ2=7.465, P=0.006).

Conclusion

VMAT combined with PD-1 inhibitor immunotherapy not only helps enhance the clinical efficacy in elderly patients with advanced NSCLC with good safety but also has positive significance in improving immunity function and pulmonary function and increasing PFS.

Open Access Full Length Article Issue
CCDC86-BHLHE40-ATF3 axis promotes aerobic glycolysis and tumor development in glioma
Genes & Diseases 2025, 12(6): 101643
Published: 12 April 2025
Abstract PDF (4.3 MB) Collect
Downloads:6

Glioma, an aggressively malignant brain tumor with a poor prognosis, comprises nearly 50% of all primary malignant brain tumors. Despite its significance in other cancers, the role of coiled-coil domain containing 86(CCDC86) in glioma remains largely unexplored. Our study revealed a significant up-regulation of CCDC86 expression in glioma tissues, correlating notably with patient age, tumor recurrence, and pathological grade. Moreover, elevated CCDC86 level was associated with a worsened prognosis among glioma patients. Functional assays demonstrated that CCDC86 knockdown attenuated glioma cell proliferation and migration while inducing apoptosis and cell cycle arrest in vitro and inhibited tumorigenesis in vivo. Furthermore, ATF3 emerged as a downstream target gene of CCDC86, as its knockdown could counteract the oncogenic effects induced by CCDC86 overexpression in glioma cells. Mechanistically, CCDC86 promoted the transcriptional regulation of ATF3 by BHLHE40 through interaction with it, stabilizing the expression of ATF3. Additionally, our investigation unveiled a potential mechanism whereby CCDC86 activated the ERK signaling pathway through ATF3, thus influencing glycolysis to drive tumor progression. In conclusion, our study highlights the pivotal role of CCDC86 in glioma progression, suggesting its potential as a therapeutic target for the development of novel glioma treatments.

Total 2